These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33233956)

  • 41. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis.
    Chang K; Svabek C; Vazquez-Guillamet C; Sato B; Rasche D; Wilson S; Robbins P; Ulbrandt N; Suzich J; Green J; Patera AC; Blair W; Krishnan S; Hotchkiss R
    Crit Care; 2014 Jan; 18(1):R3. PubMed ID: 24387680
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cancer-associated fibroblasts promote PD-L1 expression in mice cancer cells via secreting CXCL5.
    Li Z; Zhou J; Zhang J; Li S; Wang H; Du J
    Int J Cancer; 2019 Oct; 145(7):1946-1957. PubMed ID: 30873585
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
    Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
    Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Upregulation of PD-1 follows tumour development in the AOM/DSS model of inflammation-induced colorectal cancer in mice.
    Yassin M; Sadowska Z; Djurhuus D; Nielsen B; Tougaard P; Olsen J; Pedersen AE
    Immunology; 2019 Sep; 158(1):35-46. PubMed ID: 31429085
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models.
    Lakins MA; Koers A; Giambalvo R; Munoz-Olaya J; Hughes R; Goodman E; Marshall S; Wollerton F; Batey S; Gliddon D; Tuna M; Brewis N
    Clin Cancer Res; 2020 Aug; 26(15):4154-4167. PubMed ID: 32345647
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer.
    Gong B; Kiyotani K; Sakata S; Nagano S; Kumehara S; Baba S; Besse B; Yanagitani N; Friboulet L; Nishio M; Takeuchi K; Kawamoto H; Fujita N; Katayama R
    J Exp Med; 2019 Apr; 216(4):982-1000. PubMed ID: 30872362
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
    Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy.
    Wang X; Yang X; Zhang C; Wang Y; Cheng T; Duan L; Tong Z; Tan S; Zhang H; Saw PE; Gu Y; Wang J; Zhang Y; Shang L; Liu Y; Jiang S; Yan B; Li R; Yang Y; Yu J; Chen Y; Gao GF; Ye Q; Gao S
    Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6640-6650. PubMed ID: 32161124
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling.
    Passariello M; D'Alise AM; Esposito A; Vetrei C; Froechlich G; Scarselli E; Nicosia A; De Lorenzo C
    Sci Rep; 2019 Sep; 9(1):13125. PubMed ID: 31511565
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer.
    Zhao S; Ren S; Jiang T; Zhu B; Li X; Zhao C; Jia Y; Shi J; Zhang L; Liu X; Qiao M; Chen X; Su C; Yu H; Zhou C; Zhang J; Camidge DR; Hirsch FR
    Cancer Immunol Res; 2019 Apr; 7(4):630-643. PubMed ID: 30755403
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.
    Li P; Huang T; Zou Q; Liu D; Wang Y; Tan X; Wei Y; Qiu H
    J Immunol; 2019 May; 202(10):3065-3075. PubMed ID: 30979816
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice.
    Bastaki S; Aravindhan S; Ahmadpour Saheb N; Afsari Kashani M; Evgenievich Dorofeev A; Karoon Kiani F; Jahandideh H; Beigi Dargani F; Aksoun M; Nikkhoo A; Masjedi A; Mahmoodpoor A; Ahmadi M; Dolati S; Namvar Aghdash S; Jadidi-Niaragh F
    Life Sci; 2021 Feb; 266():118847. PubMed ID: 33309720
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy.
    Cai S; Chen Z; Wang Y; Wang M; Wu J; Tong Y; Chen L; Lu C; Yang H
    Theranostics; 2021; 11(4):1970-1981. PubMed ID: 33408792
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model.
    Li J; Xu J; Yan X; Jin K; Li W; Zhang R
    Med Sci Monit; 2018 Aug; 24():5501-5508. PubMed ID: 30087314
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.
    Gordon SR; Maute RL; Dulken BW; Hutter G; George BM; McCracken MN; Gupta R; Tsai JM; Sinha R; Corey D; Ring AM; Connolly AJ; Weissman IL
    Nature; 2017 May; 545(7655):495-499. PubMed ID: 28514441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.